Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DrugBank Accession Number
DB11044
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)hemagglutinin45E2IPU4MGNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30US flag
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines And Diagnostics, Inc.2011-07-012012-06-30US flag
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCatalent Belgium Sa2017-07-012018-06-30US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
293LSV29OL
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionInfluenza, Human3
4Enrolling by InvitationTreatmentInfertility1
4Enrolling by InvitationTreatmentInfertility / Recurrent Miscarriages1
3CompletedPreventionFlu caused by Influenza2
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedBasic ScienceImmune Response1
Not AvailableRecruitingNot AvailableFetal Malformation / Influenza, Human / Pregnant State1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
KitTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:05 / Updated on June 12, 2020 16:53